Clinical Cancer Research, Vol 2, Issue 8 1411-1416, Copyright © 1996 by American Association for Cancer Research

ARTICLES

Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer

Y Ohta, Y Endo, M Tanaka, J Shimizu, M Oda, Y Hayashi, Y Watanabe and T Sasaki
Department of Surgery I, School of Medicine and Department of Experimental Therapeutics, Cancer Research Institute, Kanazawa University, Kanazawa 920, Japan.

The expression of mRNAs for vascular endothelial growth factor (VEGF) was examined in 42 cases of primary lung cancer tissues (18 adenocarcinomas, 18 squamous cell carcinomas, 2 large cell carcinomas, 3 small cell carcinomas, and 1 adenoid cystic carcinoma) and 4 human lung cancer cell lines. As seen by reverse transcription-PCR analysis, VEGF mRNAs were expressed predominantly as transcripts for the secretory forms of VEGF (VEGF121 and VEGF165), both in resected lung cancer tissues and in human lung cancer cell lines. The positive ratios of VEGF mRNA according to pathological type were 66.7% (12 of 18) in adenocarcinoma, 72.2% (13 of 18) in squamous cell carcinoma, 100% (2 of 2) in large cell carcinoma, and 67% (2 of 3) in small cell carcinoma. The relative antigen levels of VEGF detected by immunohistochemical examination almost coincided with the relative VEGF mRNA expression levels. Also, we examined the expression of basic fibroblast growth factor mRNA in the same tumor specimens. However, no significant correlation was found between the VEGF and basic fibroblast growth factor mRNA expression levels. We assessed the relationship between the VEGF121 mRNA expression level and the survival period in patients (n = 17) who underwent a curative operation at stage I of the disease. The median survival of the VEGF high-expression group was 8 months, and that of the VEGF low-expression group was 151 months. The 3- and 5-year survival rates of the high-expression group (n = 6) were 50.0% and 16.7%, respectively. On the other hand, those of the low expression group (n = 11) were 90.9% and 77.9%, respectively. The difference in survival between the two groups was significant (P < 0.05). Among eight cases of long-term survival beyond 5 years, seven cases had low or no VEGF121 mRNA expression. In contrast, among 18 cases with VEGF121 mRNA overexpression, 17 cases died due to recurrence. As a marker of tumor angiogenesis, the VEGF121 mRNA expression level may be a significant prognostic indicator of lung cancers in early stages.

This article has been cited by other articles:

				M. R. McClelland, S. L. Carskadon, L. Zhao, E. S. White, D. G. Beer, M. B. Orringer, A. Pickens, A. C. Chang, and D. A. Arenberg Diversity of the Angiogenic Phenotype in Non-Small Cell Lung Cancer Am. J. Respir. Cell Mol. Biol., March 1, 2007; 36(3): 343 - 350. [Abstract] [Full Text] [PDF]

				A. L. Mulkeen, T. Silva, P. S. Yoo, J. C. Schmitz, E. Uchio, E. Chu, and C. Cha Short Interfering RNA-Mediated Gene Silencing of Vascular Endothelial Growth Factor: Effects on Cellular Proliferation in Colon Cancer Cells Arch Surg, April 1, 2006; 141(4): 367 - 374. [Abstract] [Full Text] [PDF]

				Y. Ohta, Y. Shimizu, H. Minato, I. Matsumoto, M. Oda, and G. Watanabe Results of Initial Operations in Non-Small Cell Lung Cancer Patients With Single-Level N2 Disease Ann. Thorac. Surg., February 1, 2006; 81(2): 427 - 433. [Abstract] [Full Text] [PDF]

				M. Tamura, M. Oda, Y. Tsunezuka, I. Matsumoto, K. Kawakami, and G. Watanabe Vascular endothelial growth factor expression in metastatic pulmonary tumor from colorectal carcinoma: Utility as a prognostic factor J. Thorac. Cardiovasc. Surg., October 1, 2004; 128(4): 517 - 522. [Abstract] [Full Text] [PDF]

				C. A Yi, K. S. Lee, E. A Kim, J. Han, H. Kim, O J. Kwon, Y. J. Jeong, and S. Kim Solitary Pulmonary Nodules: Dynamic Enhanced Multi-Detector Row CT Study and Comparison with Vascular Endothelial Growth Factor and Microvessel Density Radiology, October 1, 2004; 233(1): 191 - 199. [Abstract] [Full Text] [PDF]

				W Hilbe, S Dirnhofer, F Oberwasserlechner, T Schmid, E Gunsilius, G Hilbe, E Woll, and C M Kahler CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer J. Clin. Pathol., September 1, 2004; 57(9): 965 - 969. [Abstract] [Full Text] [PDF]

				C. Monnerat, R. Henriksson, T. Le Chevalier, S. Novello, P. Berthaud, S. Faivre, and E. Raymond Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer Ann. Onc., February 1, 2004; 15(2): 316 - 323. [Abstract] [Full Text] [PDF]

				K. Fujimoto, T. Abe, N. L. Muller, H. Terasaki, S. Kato, J. Sadohara, R. Kono, O. Edamitsu, T. Ishitake, A. Hayashi, et al. Small Peripheral Pulmonary Carcinomas Evaluated with Dynamic MR Imaging: Correlation with Tumor Vascularity and Prognosis Radiology, June 1, 2003; 227(3): 786 - 793. [Abstract] [Full Text] [PDF]

				M. Braga-Basaria and M. D. Ringel Beyond Radioiodine: A Review of Potential New Therapeutic Approaches for Thyroid Cancer J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1947 - 1960. [Abstract] [Full Text] [PDF]

				E S Bamberger and C W Perrett Angiogenesis in epithelian ovarian cancer Mol. Pathol., December 1, 2002; 55(6): 348 - 359. [Abstract] [Full Text] [PDF]

				M. Lucchi, A. Mussi, G. Fontanini, P. Faviana, A. Ribechini, and C. A. Angeletti Small cell lung carcinoma (SCLC): the angiogenic phenomenon Eur. J. Cardiothorac. Surg., June 1, 2002; 21(6): 1105 - 1110. [Abstract] [Full Text] [PDF]

				Y. Ohta, N. Ohta, M. Tamura, J. Wu, Y. Tsunezuka, M. Oda, and G. Watanabe Vascular Endothelial Growth Factor Expression in Airways of Patients With Lung Cancer* : A Possible Diagnostic Tool of Responsive Angiogenic Status on the Host Side Chest, May 1, 2002; 121(5): 1624 - 1627. [Abstract] [Full Text] [PDF]

				Y. Ohta, M. Oda, J. Wu, Y. Tsunezuka, M. Hiroshi, A. Nonomura, and G. Watanabe Can tumor size be a guide for limited surgical intervention in patients with peripheral non-small cell lung cancer? Assessment from the point of view of nodal micrometastasis J. Thorac. Cardiovasc. Surg., November 1, 2001; 122(5): 900 - 906. [Abstract] [Full Text] [PDF]

				T. Hayashibara, Y. Yamada, T. Miyanishi, H. Mori, T. Joh, T. Maeda, N. Mori, T. Maita, S. Kamihira, and M. Tomonaga Vascular Endothelial Growth Factor and Cellular Chemotaxis: A Possible Autocrine Pathway in Adult T-Cell Leukemia Cell Invasion Clin. Cancer Res., September 1, 2001; 7(9): 2719 - 2726. [Abstract] [Full Text] [PDF]

				S. Wellmann, T. Taube, K. Paal, H. Graf v. Einsiedel, W. Geilen, G. Seifert, C. Eckert, G. Henze, and K. Seeger Specific Reverse Transcription-PCR Quantification of Vascular Endothelial Growth Factor (VEGF) Splice Variants by LightCycler Technology Clin. Chem., April 1, 2001; 47(4): 654 - 660. [Abstract] [Full Text] [PDF]

				M. Kara, Y. Ohta, Y. Tanaka, M. Oda, and Y. Watanabe Autocrine motility factor receptor expression in patients with stage I non-small cell lung cancer Ann. Thorac. Surg., March 1, 2001; 71(3): 944 - 948. [Abstract] [Full Text] [PDF]

				M. S. Gordon, K. Margolin, M. Talpaz, G. W. Sledge Jr, E. Holmgren, R. Benjamin, S. Stalter, S. Shak, and D. C. Adelman Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer J. Clin. Oncol., February 1, 2001; 19(3): 843 - 850. [Abstract] [Full Text] [PDF]

				A. Yuan, C.-J. Yu, S.-H. Kuo, W.-J. Chen, F.-Y. Lin, K.-T. Luh, P.-C. Yang, and Y.-C. Lee Vascular Endothelial Growth Factor 189 mRNA Isoform Expression Specifically Correlates With Tumor Angiogenesis, Patient Survival, and Postoperative Relapse in Non-Small-Cell Lung Cancer J. Clin. Oncol., January 15, 2001; 19(2): 432 - 441. [Abstract] [Full Text] [PDF]

				H. Chen, A. T. Treweeke, D. C. West, K. J. Till, J. C. Cawley, M. Zuzel, and C. H. Toh In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells Blood, November 1, 2000; 96(9): 3181 - 3187. [Abstract] [Full Text] [PDF]

				K. Tae, A. K. El-Naggar, E. Yoo, L. Feng, J. J. Lee, W. K. Hong, W. N. Hittelman, and D. M. Shin Expression of Vascular Endothelial Growth Factor and Microvessel Density in Head and Neck Tumorigenesis Clin. Cancer Res., July 1, 2000; 6(7): 2821 - 2828. [Abstract] [Full Text]

				G. Stockhammer, W. Poewe, S. Burgstaller, F. Deisenhammer, A. Muigg, S. Kiechl, E. Schmutzhard, H. Maier, S. Felber, P. Schumacher, et al. Vascular endothelial growth factor in CSF: A biological marker for carcinomatous meningitis Neurology, April 25, 2000; 54(8): 1670 - 1676. [Abstract] [Full Text] [PDF]

				Y. Ohta, H. Nozawa, Y. Tanaka, M. Oda, and Y. Watanabe INCREASED VASCULAR ENDOTHELIAL GROWTH FACTOR AND VASCULAR ENDOTHELIAL GROWTH FACTOR-C AND DECREASED NM23 EXPRESSION ASSOCIATED WITH MICRODISSEMINATION IN THE LYMPH NODES IN STAGE I NON-SMALL CELL LUNG CANCER J. Thorac. Cardiovasc. Surg., April 1, 2000; 119(4): 804 - 813. [Abstract] [Full Text] [PDF]

				Y. Ohta, Y. Tanaka, T. Hara, M. Oda, S.-i. Watanabe, J. Shimizu, and Y. Watanabe Clinicopathological and biological assessment of lung cancers with pleural dissemination Ann. Thorac. Surg., April 1, 2000; 69(4): 1025 - 1029. [Abstract] [Full Text] [PDF]

				N. Munshi, J. E. Groopman, P. S. Gill, and R. K. Ganju c-Src Mediates Mitogenic Signals and Associates with Cytoskeletal Proteins upon Vascular Endothelial Growth Factor Stimulation in Kaposi's Sarcoma Cells J. Immunol., February 1, 2000; 164(3): 1169 - 1174. [Abstract] [Full Text] [PDF]

				Y. Ohta, Y. Tomita, M. Oda, S. Watanabe, S. Murakami, and Y. Watanabe Tumor angiogenesis and recurrence in stage I non-small cell lung cancer Ann. Thorac. Surg., September 1, 1999; 68(3): 1034 - 1038. [Abstract] [Full Text] [PDF]

				M. Takahama, M. Tsutsumi, T. Tsujiuchi, K. Nezu, K. Kushibe, S. Taniguchi, Y. Kotake, and Y. Konishi Enhanced Expression of Tie2, Its Ligand Angiopoietin-1, Vascular Endothelial Growth Factor, and CD31 in Human Non-Small Cell Lung Carcinomas Clin. Cancer Res., September 1, 1999; 5(9): 2506 - 2510. [Abstract] [Full Text] [PDF]

				M. Nishizaki, T. Fujiwara, T. Tanida, A. Hizuta, H. Nishimori, T. Tokino, Y. Nakamura, M. Bouvet, J. A. Roth, and N. Tanaka Recombinant Adenovirus Expressing Wild-Type p53 Is Antiangiogenic: A Proposed Mechanism for Bystander Effect Clin. Cancer Res., May 1, 1999; 5(5): 1015 - 1023. [Abstract] [Full Text] [PDF]

				W. T. Bellamy, L. Richter, Y. Frutiger, and T. M. Grogan Expression of Vascular Endothelial Growth Factor and Its Receptors in Hematopoietic Malignancies Cancer Res., February 1, 1999; 59(3): 728 - 733. [Abstract] [Full Text] [PDF]

				D. S. Winlaw Angiogenesis in the Pathobiology and Treatment of Vascular and Malignant Diseases Ann. Thorac. Surg., October 1, 1997; 64(4): 1204 - 1211. [Abstract] [Full Text]